Global Angina Pectoris Treatment Market Size By Type (Antiplatelet agents, Beta-adrenergic blocking agents), By Application (Hospitals, Clinic), By Region, And Segment Forecasts, 2023 to 2032

lobal Angina Pectoris Treatment Market Report Description

The Global Angina Pectoris Treatment Market was valued at USD 9.8 billion in 2023 and is projected to surpass USD 15.6 billion by 2031, growing at a CAGR of 6.0% during the forecast period from 2023 to 2031. The growth of this market is primarily driven by the increasing prevalence of cardiovascular diseases globally, the rise in sedentary lifestyles, unhealthy dietary habits, and the growing geriatric population.

Angina pectoris, a symptom of coronary artery disease (CAD), remains a significant health concern worldwide. The demand for effective treatment options such as anti-anginal drugs, beta-blockers, calcium channel blockers, nitrates, and advanced surgical interventions like angioplasty and bypass surgery is on the rise. Increasing R&D activities, the introduction of novel drug formulations, and enhanced healthcare infrastructure are contributing to market expansion.

Drivers:

Rising Prevalence of Cardiovascular Diseases:

The increasing incidence of lifestyle-associated diseases such as hypertension, obesity, and diabetes significantly contributes to the rising cases of angina pectoris globally.

Technological Advancements in Treatment Options:

Innovations in drug formulations, personalized medicine, and minimally invasive surgical procedures have positively impacted treatment efficacy, driving market growth.

Increasing Geriatric Population:

The global aging population is at higher risk of developing angina pectoris, thus fueling the demand for advanced treatment solutions.

Restraints:

High Treatment Costs:

Advanced therapies, surgeries, and long-term medication usage for angina pectoris can be costly, limiting access in low-income regions.

Adverse Drug Reactions:

Some angina treatment drugs are associated with side effects such as headaches, dizziness, and hypotension, potentially limiting patient compliance.

Opportunity:

Emerging Markets in Asia-Pacific and Latin America:

Rapidly developing healthcare infrastructure, increasing healthcare awareness, and rising disposable income in these regions present lucrative market opportunities.

Personalized Medicine and Precision Cardiology:

Advancements in genomics and patient-specific treatment plans offer significant growth potential in angina pectoris management.

Market by System Type Insights:

Based on system type, the Pharmaceutical Treatment segment held the largest market share in 2023. Drugs like nitrates, beta-blockers, calcium channel blockers, and anti-platelet agents remain the first line of treatment. However, the Surgical Treatment segment is expected to witness the highest growth rate due to the increasing adoption of procedures like angioplasty and coronary artery bypass grafting (CABG) for severe cases.

Market by End-use Insights:

Hospitals dominated the market in 2023, accounting for over 50% of the revenue share. The availability of advanced treatment facilities, skilled professionals, and emergency care services drive this segment. The Ambulatory Surgical Centers (ASCs) segment is also expected to grow significantly, driven by the rising preference for minimally invasive procedures and shorter hospital stays.

Market by Regional Insights:

North America led the global angina pectoris treatment market in 2023, supported by a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and significant R&D investments. Asia-Pacific is anticipated to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure, growing awareness, and government initiatives for cardiovascular health management in countries like China and India.

Competitive Scenario:

Key players operating in the Global Angina Pectoris Treatment Market include Pfizer Inc., AstraZeneca plc, Novartis AG, Merck & Co., Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Gilead Sciences, Inc., Abbott Laboratories, and F. Hoffmann-La Roche AG. These companies focus on strategic collaborations, product innovation, and mergers & acquisitions to strengthen their market position.

Key Market Developments:

In 2023, Pfizer Inc. launched a novel anti-anginal drug with enhanced efficacy and reduced side effects for chronic stable angina.

In 2024, AstraZeneca plc announced a partnership with a leading biotech company to develop precision cardiology solutions for angina management.

In 2025, Merck & Co., Inc. expanded its cardiovascular drug portfolio through the acquisition of a biotech firm specializing in next-generation cardiovascular therapeutics.

Scope of Work – Global Angina Pectoris Treatment Market

Report Metric Details

Market Size (2023) USD 9.8 billion

Projected Market Size (2031) USD 15.6 billion

CAGR (2023-2031) 6.0%

Key Segments By System Type (Pharmaceutical Treatment, Surgical Treatment), By End-use (Hospitals, Ambulatory Surgical Centers, Clinics), By Region

Growth Drivers Rising prevalence of cardiovascular diseases, Technological advancements in treatment, Increasing geriatric population

Opportunities Emerging markets in Asia-Pacific and Latin America, Personalized medicine and precision cardiology

FAQs

1) What is the current market size of the Global Angina Pectoris Treatment Market?

The Global Angina Pectoris Treatment Market was valued at USD 9.8 billion in 2023.

2) What is the major growth driver of the Global Angina Pectoris Treatment Market?

The major growth driver is the rising prevalence of cardiovascular diseases globally.

3) Which is the largest region during the forecast period in the Global Angina Pectoris Treatment Market?

North America is expected to remain the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Angina Pectoris Treatment Market?

The Pharmaceutical Treatment segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Angina Pectoris Treatment Market?

Key players include Pfizer Inc., AstraZeneca plc, Novartis AG, Merck & Co., Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Gilead Sciences, Inc., Abbott Laboratories, and F. Hoffmann-La Roche AG.

Would you like me to prepare this as a Word document for download?